Marvel Announces Its Collaboration with FRAXA to Test MB204 In Pre-Clinical Models of Fragile X SyndromeAugust 13, 2024 9:00 AM EDT | Source: Marvel Biosciences Corp.Calgary, Alberta--(Newsfile Corp. - August 13, 2024) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to announce it has entered a collaboration with the FRAXA Research Foundation to test its lead asset MB204 in a ...